Sareum Holdings ( (GB:SAR) ) has shared an update.
Sareum Holdings PLC reported significant progress in its half-year results for the period ending December 2024, marked by the successful completion of a Phase 1 clinical trial for its lead candidate, SDC-1801, which showed promising safety and pharmacokinetic profiles for treating autoimmune diseases. The company also strengthened its patent portfolio and acquired the license for SRA737 on improved economic terms, enhancing its pipeline and positioning in the biotechnology sector. Financially, Sareum raised £1.07m post-period, bolstering its resources to advance its therapeutic candidates, with a focus on addressing unmet needs in autoimmune and cancer treatments.
More about Sareum Holdings
Sareum Holdings PLC is a biotechnology company based in Cambridge, UK, that specializes in developing next-generation kinase inhibitors for autoimmune diseases and cancer. The company focuses on creating small molecules that modify the JAK kinase family, with lead candidates including SDC-1801 for autoimmune diseases like psoriasis, and SDC-1802 for cancer immunotherapy. Sareum has also acquired the license for SRA737, a Checkpoint kinase 1 inhibitor targeting cancer cell replication and DNA damage repair.
YTD Price Performance: -50.0%
Average Trading Volume: 376,635
Technical Sentiment Signal: Buy
Current Market Cap: £16.69M
Find detailed analytics on SAR stock on TipRanks’ Stock Analysis page.